MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
46.14
+0.73
+1.61%
After Hours: 46.14 0 0.00% 17:19 12/31 EST
OPEN
45.54
PREV CLOSE
45.41
HIGH
47.31
LOW
45.21
VOLUME
924.52K
TURNOVER
--
52 WEEK HIGH
93.77
52 WEEK LOW
27.66
MARKET CAP
6.04B
P/E (TTM)
-9.5368
1D
5D
1M
3M
1Y
5Y
1D
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock
Simply Wall St · 6h ago
Top Vaxcyte Executive Makes Notable Move With Fresh Insider Stock Sale
TipRanks · 12/30/2025 02:02
Weekly Report: what happened at PCVX last week (1222-1226)?
Weekly Report · 12/29/2025 09:19
Taking Stock of Vaxcyte (PCVX): Valuation After Encouraging VAX-31 Phase 2 Results and Bullish Analyst Outlook
Simply Wall St · 12/25/2025 18:14
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
Barron‘s · 12/22/2025 13:19
Weekly Report: what happened at PCVX last week (1215-1219)?
Weekly Report · 12/22/2025 09:19
Vaxcyte Enhances Executive Severance to Align With Market
TipRanks · 12/19/2025 21:31
Vaxcyte Raises Executive Severance Multipliers in Amended Agreements
Reuters · 12/19/2025 21:11
More
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.